NO20082919L - Heteroringsubstituerte 3-alkylazetidinderivater - Google Patents

Heteroringsubstituerte 3-alkylazetidinderivater

Info

Publication number
NO20082919L
NO20082919L NO20082919A NO20082919A NO20082919L NO 20082919 L NO20082919 L NO 20082919L NO 20082919 A NO20082919 A NO 20082919A NO 20082919 A NO20082919 A NO 20082919A NO 20082919 L NO20082919 L NO 20082919L
Authority
NO
Norway
Prior art keywords
disorders
treatment
useful
compounds
receptor
Prior art date
Application number
NO20082919A
Other languages
English (en)
Inventor
Robert K Baker
Shouwu Miao
Kathleen M Rupprecht
Jeffrey J Hale
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20082919L publication Critical patent/NO20082919L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nye forbindelser med strukturformel (I) er antagonister og/eller inversagonister mot reseptoren for cannabinoid-1 (CB1), og er anvendbare ved behandling, forebygging og undertrykkelse av sykdommer formidlet av CB1-reseptoren. Forbindelsene ifølge den foreliggende oppfinnelse er anvendbare som sentraltvirkende legemidler ved behandling av psykose, hukommelsessvikt, kognitive forstyrrelser, Alzheimers sykdom, migrene, nevropati, nevro-inflammatoriske forstyrrelser, inkludert multippel sklerose og GuillainBarre-syndrom, og de inflammatoriske følgesykdommer av viral encefalitt, cerebrale vaskulære forstyrrelser og hodetraume, angstforstyrrelser, stress, epilepsi, Parkinsons sykdom, bevegelsesforstyrrelser og schizofreni. Forbindelsene er også anvendbare til behandling av stoffmisbruksforstyrrelser, behandling av overvekt eller spiseforstyrrelser, samt behandling av astma, forstoppelse, kronisk intestinal pseudoobstruksjon og cirrhose i leveren.
NO20082919A 2005-11-28 2008-06-27 Heteroringsubstituerte 3-alkylazetidinderivater NO20082919L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74018305P 2005-11-28 2005-11-28
PCT/US2006/045328 WO2007062193A1 (en) 2005-11-28 2006-11-22 Heterocycle-substituted 3-alkyl azetidine derivatives

Publications (1)

Publication Number Publication Date
NO20082919L true NO20082919L (no) 2008-08-27

Family

ID=37779312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082919A NO20082919L (no) 2005-11-28 2008-06-27 Heteroringsubstituerte 3-alkylazetidinderivater

Country Status (15)

Country Link
EP (1) EP1954692A1 (no)
KR (1) KR20080073721A (no)
AR (1) AR058199A1 (no)
BR (1) BRPI0619018A2 (no)
CR (1) CR10014A (no)
DO (1) DOP2006000261A (no)
EC (1) ECSP088477A (no)
IL (1) IL191586A0 (no)
MA (1) MA30086B1 (no)
NO (1) NO20082919L (no)
PE (1) PE20070647A1 (no)
RU (1) RU2008126248A (no)
SV (1) SV2009002917A (no)
TW (1) TW200804317A (no)
WO (1) WO2007062193A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906652B2 (en) * 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011502119A (ja) * 2007-10-24 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｂ−１アンタゴニスト／逆アゴニストの合成及び結晶体
EP2611788B1 (en) 2010-09-03 2017-04-12 University of Florida Research Foundation, Incorporated Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
AU2004252109B2 (en) * 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
CA2606188A1 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity

Also Published As

Publication number Publication date
WO2007062193A1 (en) 2007-05-31
SV2009002917A (es) 2009-02-19
CR10014A (es) 2008-07-29
PE20070647A1 (es) 2007-08-11
KR20080073721A (ko) 2008-08-11
MA30086B1 (fr) 2008-12-01
TW200804317A (en) 2008-01-16
DOP2006000261A (es) 2007-07-15
ECSP088477A (es) 2008-06-30
BRPI0619018A2 (pt) 2016-11-29
IL191586A0 (en) 2008-12-29
EP1954692A1 (en) 2008-08-13
AR058199A1 (es) 2008-01-23
RU2008126248A (ru) 2010-01-10

Similar Documents

Publication Publication Date Title
NO20082919L (no) Heteroringsubstituerte 3-alkylazetidinderivater
DE60316829D1 (de) Substituierte furoä2,3-büpyridin derivate
NO20060141L (no) Substituerte 3-alkyl- og 3-alkenylazetidinderivater
DE60334787D1 (de) Substituierte amide
EP1492784A4 (en) SUBSTITUTED 2,3-DIPHENYLPYRIDINES
JO2482B1 (en) Amide compounds by replacement
WO2003082190A3 (en) Spirocyclic amides as cannabinoid receptor modulators
WO2003063781A3 (en) Substituted imidazoles as cannabinoid receptor modulators
WO2004058145A3 (en) Substituted amides
WO2004029204A3 (en) Substituted pyrimidines
ATE452890T1 (de) Substituierte naphthyridinonderivate
AU2016299485B2 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
WO2003086288A3 (en) Bicyclic amides
ATE501151T1 (de) Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren
WO2005027837A3 (en) Substituted sulfonamides
WO2008024284A3 (en) Sulfonylated piperazines as cannabinoid-1 receptor modulators
NO20063381L (no) CB1 modulatorforbindelser
NO20054206L (no) Bifenylderivater
WO2007136607A3 (en) Substituted esters as cannabinoid-1 receptor modulators
WO2004069794A3 (en) New arylpiperazinyl compounds
TW200400185A (en) Derives de 1-piperazinylacylpiperidine substitues, leur preparation et leur application en therapeutique
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
WO2007064566A3 (en) Heterocycle-substituted 3-alkyl azetidine derivatives
WO2006041797A3 (en) Acyclic hydrazides as cannabinoid receptor modulators
WO2010012811A3 (en) Method for screening of 5ht7 receptor ligands based on a new pharmacophore model and a descriptor's profile filter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application